The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes

Makady, Nafie F.; Ramzy, David; Ghaly, Ramy; Abdel-Malek, Raafat; Shohdy, Kyrillus S.

doi:10.1016/j.clml.2020.11.025

Cited by 20 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…57,59 A systematic review found no significant difference in objective response rates when comparing CHOP and DA-EPOCH, however, the use of more aggressive chemotherapy resulted in improved overall survival. 63 The addition of bortezomib to EPOCH has yielded excellent results in some case series. 64,65 The International Prognostic Index (IPI) has been shown to be a useful prognostic tool, 56,60 and advanced stage is associated with a higher risk of relapse.…”

Section: Treatmentmentioning

confidence: 99%

Plasmablastic lymphoma: An update

Bailly

Jenkins

Chetty

et al. 2022

Int J Lab Hematology

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a highly aggressive B cell non-Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. Although PBL is rare globally, South Africa has a high burden of HIV infection leading to a higher incidence of PBL in the region. Laboratory features in PBL may overlap with plasmablastic myeloma and other large B cell lymphomas with plasmablastic or immunoblastic morphology leading to diagnostic dilemmas. There are, however, pertinent distinguishing laboratory features in PBL such as a plasma cell immunophenotype with MYC overexpression, expression of Epstein-Barr virus-encoded small RNAs and lack of anaplastic lymphoma kinase (ALK) expression. This review aims to provide a summary of current knowledge in PBL, focusing on the epidemiology, pathophysiology, laboratory diagnosis and clinical management.

show abstract

Section: Treatmentmentioning

confidence: 99%

Plasmablastic lymphoma: An update

Bailly

Jenkins

Chetty

et al. 2022

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…A recent review of 173 patients with PBL supports a wide range of therapies. None received daratumumab [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

Lee

Martin

Abdulhaq

2022

Case Reports in Hematology

View full text Add to dashboard Cite

Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. Gorham’s lymphangiomatosis or Gorham–Stout disease (GSD) is a rare skeletal condition of unknown etiology characterized by progressive bone loss and nonmalignant proliferation of vascular and lymphatic channels within the affected bone. Neither disease has a standard of care. We present a 23-year-old HIV-negative woman with GSD, managed medically with octreotide and sirolimus, who developed PBL. After progressing on V-EPOCH (bortezomib, etoposide, vincristine, cyclophosphamide, doxorubicin, and prednisone), she was treated with daratumumab, lenalidomide, and dexamethasone (DRD) therapy and achieved complete remission after two cycles with progression after eight cycles. This is a report of treatment of PBL with DRD therapy. Clinical investigations of the DRD regimen in PBL in conjunction with other agents to improve both depth and durability of response are warranted.

show abstract

“…Initially described in HIV-positive individuals, PBL is frequently associated with EBV infection ( 1 ). Without specific care for PBL, intensive regimen like EPOCH only had 47.4–62.0% CR in fit patients ( 14 ). However, some reports of small-scale cases showed anti-PBL activity of non-cytotoxic agents such as bortezomib and lenalidomide ( 15 ).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

et al. 2021

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant status, or immunosenescence. Given its rarity, there is no specific standard treatment for PBL. However, small case series have shown that intensive chemotherapies combined with anti-myeloma agents such as bortezomib and lenalidomide were effective in treating PBL. Unfortunately, some fragile patients could not tolerate intensive chemotherapeutic regimens, especially the elderly patients. Here we presented a 76-year-old female PBL patient refractory to miniCHOP regimen combined with bortezomib but achieved complete remission when treated with tislelizumab combined with lenalidomide, indicating that immune therapy may be a potential treatment for PBL. To our knowledge, this is the first chemoresistant PBL patient that has been successfully treated with checkpoint inhibitor plus lenalidomide, thus providing new insight towards PBL management.

show abstract

The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes

Cited by 20 publications

References 37 publications

Plasmablastic lymphoma: An update

Plasmablastic lymphoma: An update

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

Contact Info

Product

Resources

About